Supernus Pharmaceuticals (SUPN) opened 2026 with Q1 revenue of US$207.7 million and a basic EPS loss of US$0.04, alongside a net loss of US$2.3 million, while its trailing twelve month figures show revenue of US$776.8 million and a net loss of US$29.0 million, equivalent to a basic EPS loss of US$0.51. The company has seen quarterly revenue move from US$149.8 million in Q1 2025 to US$207.7 million in Q1 2026, with basic EPS shifting from a loss of US$0.21 to a smaller loss of US$0.04 over the same stretch. Overall, the latest numbers point to a business scaling its top line while still working through loss-making margins that investors will watch closely.

See our full analysis for Supernus Pharmaceuticals.

With the headline figures on the table, the next step is to see how these results line up with the widely followed growth and risk narratives around Supernus and where those stories might need updating.

Losses Persist On US$776.8 Million Trailing Revenue

• Over the last twelve months, Supernus generated US$776.8 million in revenue and reported a net loss of US$29.0 million, which works out to a basic EPS loss of US$0.51.
• Analysts' view that higher CNS demand can support margin expansion meets a mixed picture here, as trailing revenue is sizeable while losses have grown at about 37.1% per year over five years. This suggests that higher sales alone have not yet translated into consistent profitability.

Quarterly Swings Highlight Earnings Volatility

• Recent quarters have moved between profit and loss, from Q2 2025 net income of US$22.5 million with basic EPS of US$0.40 to Q3 2025 net loss of US$45.1 million with basic EPS loss of US$0.80, and then to a much smaller Q1 2026 net loss of US$2.3 million with basic EPS loss of US$0.04.
• Bears focus on rising SG&A and R&D and point to this pattern as evidence of pressure, with recent commentary citing persistent operating losses and reliance on a few products. The wide swing from a US$22.5 million profit in Q2 2025 to a US$45.1 million loss in Q3 2025 illustrates how earnings can move sharply when costs and product concentration issues show up in a single period.

What skeptics are watching is how quickly these swings settle down as new products scale, and how that lines up with the risks around pricing pressure and heavier spending on launches and the pipeline. 🐻 Supernus Pharmaceuticals Bear Case

Valuation Signals Versus Profit Track Record

• At a share price of US$51.45, the stock trades at a P/S of 3.8x versus a cited US pharmaceuticals average of 5.5x and peer average of 23.9x, and at a discount to the stated DCF fair value of US$194.83 and to the single allowed analyst target of US$62.83.
• The consensus narrative argues that expanding the CNS portfolio and pipeline can support higher earnings. However, the trailing loss of US$29.0 million and five-year loss growth of about 37.1% per year sit in contrast to those expectations, so the valuation gap to both the DCF fair value and the US$62.83 target is likely to be judged against whether future margins can differ meaningfully from the current loss-making record.

Bulls point to the combination of lower P/S and the gap to DCF fair value as support for their case, while the trailing loss profile keeps the bar high for the next few sets of numbers to support that view. 🐂 Supernus Pharmaceuticals Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Supernus Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment split between a lower P/S and a history of losses, it helps to see the full picture for yourself rather than rely on headlines. Take a closer look at the company's mix of concerns and potential upside with 4 key rewards and 1 important warning sign

See What Else Is Out There

Supernus is still working through losses and sharp earnings swings despite US$776.8 million in trailing revenue, which keeps its profit track record under pressure.

If that kind of volatility makes you uneasy, it is worth checking stocks that screen well for resilience and steadier fundamentals through the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.